Here are the best biotech stocks for investors looking for market-beating performance.
News & Analysis: Global Blood Therapeutics
Here's why it is now a great opportunity to buy a company making an innovative therapy for patients with sickle cell disease.
Promising new drugs will drive these companies' stocks skyward.
On Wednesday, investors will learn the progress of its sickle cell disease drug launch.
Targeted therapies for treating sickle cell disease are finally here after a 60-year wait.
Despite fears of a COVID-19 pandemic, these two stocks are worth considering.
These companies could kick off the year with big announcements and deliver gains to savvy investors.
Patients who inherit life-threatening blood disorders have some important new treatment options.
Here's why the FDA recently approved five new drugs way ahead of schedule.
Transformative new therapies are changing the treatment landscape for patients with sickle cell disease, and savvy investors can benefit in this David-versus-Goliath scenario. Which one is the better buy today?